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Abstract
Background: Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients
with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of anthracyclines,
but in the USA and some European countries, its use had been restricted to adults with advanced breast cancer
receiving a cumulative doxorubicin (an anthracycline) dose > 300mg/m2. We evaluated the off-label use of dexrazoxane
as a cardioprotectant in adult patients with preexisting cardiomyopathy, undergoing anthracycline chemotherapy.
Methods: Between July 2015 and June 2017, five consecutive patients, with preexisting, asymptomatic, systolic left
ventricular (LV) dysfunction who required anthracycline-based chemotherapy, were concomitantly treated with off-label
dexrazoxane, administered 30min before each anthracycline dose, regardless of cancer type or stage. Demographic,
cardiovascular, and cancer-related outcomes were compared to those of three consecutive patients with asymptomatic
cardiomyopathy treated earlier at the same hospital without dexrazoxane.
Results: Mean age of the five dexrazoxane-treated patients and three patients treated without dexrazoxane was 70.6
and 72.6 years, respectively. All five dexrazoxane-treated patients successfully completed their planned chemotherapy
(doxorubicin, 280 to 300mg/m2). With dexrazoxane therapy, changes in LV systolic function were minimal with mean
left ventricular ejection fraction (LVEF) decreasing from 39% at baseline to 34% after chemotherapy. None of the
dexrazoxane-treated patients experienced symptomatic heart failure or elevated biomarkers (cardiac troponin I or
brain natriuretic peptide). Of the three patients treated without dexrazoxane, two received doxorubicin (mean dose,
210mg/m2), and one received daunorubicin (540mg/m2). Anthracycline therapy resulted in a marked reduction in LVEF
from 42.5% at baseline to 18%. All three developed symptomatic heart failure requiring hospitalization and intravenous
diuretic therapy. Two of them died from cardiogenic shock and multi-organ failure.
Conclusion: The concomitant administration of dexrazoxane in patients with preexisting cardiomyopathy permitted
successful delivery of anthracycline-based chemotherapy without cardiac decompensation. Larger prospective trials are
warranted to examine the use of dexrazoxane as a cardioprotectant in patients with preexisting cardiomyopathy who
require anthracyclines.
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Introduction
Since their introduction in the early 1950s, anthracyclines
have been widely used for treating a variety of solid and
hematologic cancers in both adults and children [1].
However, cardiotoxicity has limited their use in patients
with preexisting cardiomyopathy or symptomatic heart
failure [2]. In the early 1970s, Eugene Herman discovered
that dexrazoxane reduced anthracycline-induced cardio-
toxicity [3]. In 1995, the US Food and Drug Administra-
tion (FDA) approved dexrazoxane for cardioprotection in
women receiving fluorouracil, doxorubicin, and cyclo-
phosphamide (FDC) chemotherapy for breast cancer and
who required a cumulative doxorubicin dose > 350mg/m2
[4]. Similarly, in 2011 the European Medicines Agency
(EMA) decided that the use of dexrazoxane should be re-
stricted to adult breast cancer patients requiring a cumu-
lative dose of doxorubicin > 300mg/m2 or a cumulative
dose of epirubicin > 540mg/m2 [5]. This limitation comes
from debatable concerns that dexrazoxane might reduce
anti-tumor response rates and increase the risk of second-
ary hematologic malignancies [6–9].
We sought to determine whether dexrazoxane would be
cardioprotective in patients without the current indica-
tions for its use. Here, we present a consecutive series of
patients from a single institution with preexisting cardio-
myopathy, who were treated with anthracyclines, and
compare their cardiovascular and cancer-related outcomes
to those of similar patients who subsequently received
concomitant off-label dexrazoxane with anthracycline-
based chemotherapy.
Methods
In the two years preceding the initiation of the Lahey
cardio-oncology program (July 2013 to June 2015), we
noted that several patients with either preexisting cardio-
myopathy, or those who experienced anthracycline-in-
duced cardiomyopathy, developed worsening LV systolic
function and major adverse cardiovascular events including
heart failure, cardiogenic shock, arrhythmias, and cardio-
vascular death, despite the use of maximally tolerated,
guideline-directed heart failure therapy.
After evaluating the evidence on the use of dexrazoxane
for cardioprotection against anthracycline-induced cardio-
toxicity, we developed a clinical practice algorithm (Fig. 1)
based on consensus among internal and external experts
in cardio-oncology, hematology-oncology, and heart fail-
ure to use off-label concomitant dexrazoxane, in addition
to guideline-directed heart failure therapy and close car-
diac monitoring, in subsequent patients with preexisting
cardiomyopathy who required anthracycline-based chemo-
therapy. Since this was a consensus-based clinical practice
guideline, and not an experimental research study, institu-
tional review board approval was not required.
Patient selection
Beginning in July 2015, five consecutive patients with
preexisting asymptomatic LV systolic dysfunction, who
required anthracycline-based chemotherapy, were
treated with dexrazoxane as a cardioprotectant as per
our consensus protocol. Three consecutive patients with
preexisting asymptomatic LV systolic dysfunction who
received anthracycline based chemotherapy between July
2013 and June 2015 were identified for comparison.
Cardioprotection protocol
All five patients received off-label dexrazoxane in a 10:1 ra-
tio of dexrazoxane to doxorubicin, or at a reduced dose
based on their creatinine clearance, 30min before each
anthracycline dose [4] throughout the therapy, regardless
of cancer type or stage. All patients also received max-
imally tolerated, guideline-directed heart failure therapy
[10]. Complete blood count, liver function, kidney func-
tion, and zinc, iron, and magnesium concentrations were
assessed at baseline and after each chemotherapy cycle.
Serum cardiac biomarkers including cardiac troponin I
(cTnI) and brain natriuretic peptide (BNP) were measured
before and within 48 h after each dose of anthracyclines
[11–13], as well as 6months after completion of chemo-
therapy. Echocardiograms were obtained at baseline, before
every subsequent or alternate cycle of chemotherapy (as
per the primary cardiology or cardio-oncology provider),
immediately after the completion of anthracycline-based
chemotherapy, and 6months later [12].
Patient follow-up
All patients receiving dexrazoxane were followed in our
cardio-oncology clinic, either before each subsequent or al-
ternate cycle of anthracycline chemotherapy, as deemed ap-
propriate by their providers. All patients were thoroughly
examined for signs or symptoms of heart failure. We also
collected data on cardiovascular and cancer-related out-
comes (asymptomatic LV systolic dysfunction, heart failure,
arrhythmias, cardiogenic shock, elevated serum cardiac
biomarker concentrations defined as cTnI > 0.03 ng/mL
and/or BNP > 250 pg/mL, tumor response, secondary ma-
lignancy, or death from any cause) during follow-up.
Patients were followed until death or loss to follow-up.
Results
Patients treated without Dexrazoxane
Between July 2013 and June 2015, we had treated three
consecutive male patients treated with anthracycline but
without dexrazoxane (patients #1, #2, and #3; mean age,
72.6 years) at the Lahey Hospital and Medical Center. Pa-
tient #1 had preexisting asymptomatic non-ischemic car-
diomyopathy (LVEF 40%), patient #2 had preexisting
asymptomatic ischemic cardiomyopathy (LVEF 45%), and
patient #3 had anthracycline-induced cardiomyopathy that
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developed after receiving a cumulative daunorubicin dose
of 270mg/m2 for acute myeloid leukemia (LVEF 45%)
(Table 1). Each patient in this group had received max-
imally tolerated doses of guideline-directed heart failure
therapy. Patients #1 and #2 received doxorubicin (cumula-
tive doses of 300mg/m2 and 120mg/m2, respectively),
and patient #3 received daunorubicin (cumulative dose
540mg/m2).
All three patients in this group experienced marked
reductions in LV systolic function (the mean LVEF de-
creased from 42.5% at baseline to 18% after chemother-
apy), and developed symptomatic heart failure requiring
hospitalization and intravenous diuretic therapy, either
during or within the first six months after completion of
chemotherapy (Table 2). Patients #1 and #2 developed
fatal cardiogenic shock and multi-organ failure. Patient
#2 had advanced, diffuse, large B-cell lymphoma and
received only two cycles of anthracycline-based chemo-
therapy before experiencing heart failure, cardiogenic
shock, and death. Patient #3 had acute myeloid leukemia
and cardiomyopathy that developed during chemother-
apy with daunorubicin (LVEF 45%). He continued
therapy and received an additional 270mg/m2 of dauno-
rubicin with further worsening of his cardiomyopathy
(LVEF 30%) that persisted, despite treatment with neuro-
hormonal antagonists.
Fig. 1 Clinical protocol for patients with existing cardiomyopathy requiring anthracycline therapy
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Patients treated with Dexrazoxane
The dexrazoxane protocol was implemented in the next
five consecutive eligible patients (patients #4 through #8;
mean age, 70.6 years), one man and four women, four
with non-ischemic cardiomyopathy and one with ische-
mic cardiomyopathy. The mean pre-chemotherapy LVEF
for these five dexrazoxane-treated patients was 39%
(range, 35 to 45%) (Table 1). Patient #4 had an
implantable cardioverter-defibrillator for primary pre-
vention. All five patients received doxorubicin (280 to
300 mg/m2).
The median follow-up period was 13.5 months (range,
12–30months). Two patients treated without dexrazox-
ane died and none were lost to follow-up.
The mean post-chemotherapy LVEF in this group was
34% and all five completed planned chemotherapy without
Table 1 Clinical and Treatment Characteristics of Eight Patients with Preexisting Cardiomyopathy Undergoing Anthracycline
Chemotherapy for Any Cancer, With or Without the Cardioprotectant, Dexrazoxane
Patient #. sex;
age, years
Cancer,
Stage
Chemotherapy regimen;
anthracycline,
cumulative dose, mg/m2
Cardiac history Before the start of anthracycline
chemotherapy
LVEF, %, by time since
anthracycline therapy
ACEi Beta
Blocker
Aldosterone
Antagonist
Pre During Post 6 months
post
Without dexrazoxane (controls)
1. M; 87 PTCL, IV CHOP Doxorubicin, 300 NICM Yes Yes Yes 45 – 10 –
2. M; 66 DLBCL, IV R-EPOCH Doxorubicin, 120 Ischemic
Cardiomyopathy
Yes Yes No 40 15 – –
3. M; 65 AML, M4 Cytarabine + Daunorubicin
Daunorubicin, 540
Chemotherapy- related
cardiomyopathy
Yes No Yes 55 45 30 30
With dexrazoxane
4. F; 67a HL, IIIB ABVD Doxorubicin, 300 NICM Yes Yes No 35 35 35 25
5. F; 75 DLBCL,
IIISE
CHOP Doxorubicin, 300 NICM Yes Yes Yes 35 35 35 30
6. F 70 Ovarian, IV Doxorubicin, 280 NICM No Yes No 45 40 40 40
7. M; 73 NHL, IV ABVD Doxorubicin, 300 Ischemic cardiomyopathy Yes Yes Yes 40 40 40 40
8. F; 68 Breast, IV Doxorubicin Doxorubicin,
300
NICM Yes Yes No 40 40 40 35
LVEF left ventricular ejection fraction, ACEi angiotensin-converting enzyme inhibitors, DEX dexrazoxane, PTCL peripheral T-cell lymphoma, CHOP cyclophosphamide,
doxorubicin, vincristine, and prednisone, NICM non-ischemic cardiomyopathy, DLBCL diffuse large B-cell lymphoma, M4 acute myelomonocytic leukemia, R-EPOCH
rituximab, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin), AML acute myeloid
leukemia, ABVD Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine, HL Hodgkin lymphoma
aPatient had a defibrillator before chemotherapy
Table 2 Outcomes of Eight Patients with Preexisting Cardiomyopathy Undergoing Anthracycline Chemotherapy for Any Cancer,
With or Without The Cardioprotectant, Dexrazoxane
Patient #.
Sex; age,
years
Elevated biomarker
concentrationsa
Clinical
HF
New
arrhythmia
Clinical outcome Chemotherapy
cycles received, n
Cancer outcomes
Troponin BNP
Without dexrazoxane
1. M; 87 Not available Not available Yes NSVT Cardiogenic shock, HF, death 6 Died
2. M; 66 Not available Not available Yes No Cardiogenic shock, HF, death 3 Died
3. M; 65 Not available Not available Yes No Required ICD 2 Alive at 12 months after Allo SCT
With dexrazoxane
4. F; 67 No No No NSVT Alive at 30 months 6 Complete remission
5. F; 75 No No No No Alive at 18 months,
Needed BiV ICD implantation
6 Complete remission
6. F 70 No No No No Alive at 12 months 6 Partial response
7. M; 73 No No No No Alive at 15 months 6 Complete remission
8. F; 68 No No No NSVT Alive at 12 months 6 Complete response
NSVT Non-sustained ventricular tachycardia, HF heart failure, ICD implantable cardiodefibrillator, Allo SCT allogeneic stem cell transplantation, BiV ICD bi-ventricular
implantable cardiodefibrillator
aThreshold values for elevation were > 0.03 ng/mL for cTnI and > 250 pg/mL for BNP
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any major adverse cardiovascular events (Table 2).
Patient #5, with a preexisting left bundle branch block
and non-ischemic cardiomyopathy (baseline LVEF
35%), required cardiac resynchronization therapy with a
bi-ventricular implantable cardioverter-defibrillator
after chemotherapy, given that her LVEF persistently
remained < 35%. None of the patients experienced
symptomatic heart failure requiring intravenous diur-
esis or hospitalization, and no secondary malignancies
were detected ≥12 months after completion of
chemotherapy.
Serum concentrations of cTnI and BNP were not ele-
vated in any of the five patients. Patients #4 and #8 had
sporadic episodes of non-sustained ventricular tachycar-
dia, but no sustained arrhythmias were noted (Table 2).
Three of the five patients in this group experienced sig-
nificant neutropenia (absolute neutrophil count < 500/μL),
and two patients experienced neutropenic fever requiring
treatment with antibiotics. None of the patients developed
any detectable end-organ damage as a result. No clinically
important abnormalities were noted in any other labora-
tory parameters including serum liver function, kidney
function, and zinc, iron, and magnesium concentrations.
Discussion
The patients in our case series had preexisting cardiomy-
opathy that placed them at increased risk for cardiotoxi-
city from anthracycline-based chemotherapy. Off-label use
of concomitant dexrazoxane as a cardioprotectant allowed
successful administration of planned anthracycline-based
chemotherapy, without symptomatic cardiac decompensa-
tion. In contrast, similar patients who received anthracy-
clines without cardioprotection, experienced a significant
decline in their LVEF, coupled with adverse cardiovascular
outcomes including death. It is also important to note that
in our case series, dexrazoxane was not associated with ei-
ther a reduced anti-tumor response or the development of
secondary malignancies during the median follow-up
period of 13.5months. Our data, although limited, support
the use of concomitant dexrazoxane as a cardioprotectant
in patients with preexisting cardiomyopathy who require
anthracycline therapy.
The overlap of Cancer and cardiomyopathy
With an aging population, and with an increase in the
number of patients with cardiovascular disease (CVD) and
cancer survivors, greater overlap between CVD and can-
cer is expected [14–17]. The risk of anthracycline-induced
cardiotoxicity is increased in the elderly, patients with car-
diovascular comorbidities, and in patients receiving add-
itional cardiotoxic chemotherapies or thoracic irradiation
[18]. Our case series includes patients with preexisting LV
systolic dysfunction who are often excluded from
receiving anthracycline-based chemotherapy due to the
risk of worsening cardiomyopathy. This often results in in-
ferior cancer outcomes, or in cases where they receive
anthracyclines, increased cardiovascular morbidity and
mortality. In this case series, we report our observations
on the successful use of dexrazoxane as a cardioprotectant
in this patient population.
Anthracycline-related cardiotoxicity
Anthracyclines have been widely used to treat a variety
of solid and hematological cancers in children and adults
since the 1950s [1]. Cardiac complications were reported
a few years later [19], but anthracyclines remain one of
the most commonly used classes of chemotherapeutic
agents, given their oncologic efficacy [1].
Anthracycline-related cardiotoxicity ranges from sub-
clinical cardiomyopathy to florid heart failure. Cardio-
toxicity may occur within the first week of anthracycline
treatment or even decades later [20]; however, most
cases occur within the first year after treatment [21].
The frequency and characteristics of both clinical and
subclinical cardiotoxicity may vary between children and
adults [22]. In adult breast cancer patients, the incidence
of cardiotoxicity is approximately 9% [21]. The actual in-
cidence of late cardiotoxicity in long-term survivors of
childhood cancer is difficult to ascertain since it in-
creases with longer survival, but up to one third of child-
hood survivors have some evidence of cardiac
dysfunction, including overt heart failure [23].
Doxorubicin is not the only anthracycline associated with
cardiotoxicity; epirubicin and daunorubicin, other com-
monly used anthracyclines to treat several cancers, have
also caused similar cardiotoxicity, especially at high doses
[24–26]. In this case series as well, one of the patients in
the anthracycline-treated group who did not receive dexra-
zoxane (patient #5) experienced daunorubicin-related car-
diotoxicity resulting in cardiomyopathy and heart failure.
Anthracyclines are believed to cause cardiotoxicity by
multiple mechanisms; including both the generation of
oxygen free radicals and by inhibition of topoisomerase
2B. Substantial experimental data support the involve-
ment of iron in anthracycline-induced cardiotoxicity, in-
cluding evidence suggesting the importance of the HFE
gene in regulating cardiac iron accumulation after ex-
posure to anthracyclines, irrespective of a patient’s sys-
temic iron load [27].
Preventing cardiomyopathy
Dexrazoxane: Mechanism of action
Dexrazoxane is an iron chelator that binds free iron or
removes iron from the doxorubicin-iron complex,
thereby preventing oxygen free radical formation. This
property may explain how dexrazoxane reduces some of
the cardiotoxic effects of anthracyclines [28]. However,
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other iron chelators, such as deferasirox, or ICRF-161,
are not cardioprotective [29, 30]. Dexrazoxane also
changes the configuration of topoisomerase II [31] thus
preventing anthracyclines from binding to the topoisom-
erase II complex [32]. This may be an additional mech-
anism for the cardioprotective effects of dexrazoxane.
Dexrazoxane: Facts and fiction (Table 3)
The current approved use of dexrazoxane in adults is
based on two multicenter, randomized controlled trials
(088001 and 088006) involving more than 500 women
with advanced breast cancer [6]. In these studies, women
were randomized to receive doxorubicin, with or with-
out dexrazoxane (10:1 dexrazoxane:doxorubicin). In
study 088001, 15% of women who received dexrazoxane
and 31% of those who received placebo experienced a
cardiac event (HR 2.63, 95%CI 1.61 to 4.27). Similarly, in
study 088006, 14% of those treated with dexrazoxane ex-
perienced a cardiovascular event compared to 31%
treated with placebo (HR 2.0, 95% CI 1.01 to 3.96).
Cardiac events were defined as a decline in LVEF from
baseline ≥10% and below the institution’s lower limit of
normal (LLN), a decline in LVEF of ≥20% from baseline,
or the development of heart failure (with two or more of
the following: cardiomegaly established by radiography,
basilar rales, S3 gallop, or paroxysmal nocturnal dys-
pnea, orthopnea, or significant dyspnea on exertion) [6].
The early signal of substantial cardioprotection in these
studies, led to the use of open-label dexrazoxane in pa-
tients on placebo who had received a cumulative doxo-
rubicin dose of 300 mg/m2. These patients experienced a
marked reduction in cardiovascular events, despite the
late introduction of dexrazoxane (HR 3.5, 95% CI 2.2 to
5.7) [6, 7].
In trial 088001, the dexrazoxane group had a lower anti-
tumor response rate (complete remission and partial re-
mission) when compared to the placebo group (48% vs.
63%, P = 0.007), although the overall time-to-progression
and overall survival were not affected. Response rates were
not significantly different in trial 088006. However, despite
these disparate results, this led to a concern that dexra-
zoxane may reduce the anti-tumor efficacy of anthracy-
clines. Furthermore, in studies of children receiving
dexrazoxane, there was an initial concern of an increased
incidence of secondary malignancies, such as acute mye-
loid leukemia and myelodysplastic syndrome. Further
follow-up of those same study patients has subsequently
found that the concern for reduced oncologic efficacy was
not correct [8]. Because the maximum benefit of dexra-
zoxane was seen in patients receiving a cumulative doxo-
rubicin dose ≥300mg/m2, and out of concern for reduced
anti-tumor efficacy as well as increased risk of secondary
malignancy, the FDA and EMA restricted its use to adults
with advanced breast cancer receiving higher cumulative
doses of doxorubicin [4–8]. The most recent American
Society of Clinical Oncology guidelines also recommend
limiting the use of dexrazoxane to patients receiving a cu-
mulative doxorubicin dose > 250mg/m2 [33].
Although dexrazoxane is not approved as a cardiopro-
tectant in adults with hematologic malignancies, it has
nevertheless been used in these patients. A retrospective
analysis of adults with non-Hodgkin lymphoma treated
with anthracycline-based combination chemotherapy re-
vealed that dexrazoxane had similar cardioprotective ef-
fects [34, 35]. Dexrazoxane has also been shown to be
cardioprotective in elderly patients with acute myeloid
leukemia or small cell lung cancer [36, 37]. Similarly,
dexrazoxane provided marked cardioprotection against
epirubicin-related cardiotoxicity in patients with breast
cancer or sarcoma with no evidence of reduced antitu-
mor activity [38, 39].
Dexrazoxane has also been successfully used in chil-
dren with various solid and hematologic cancers. The
Dana-Farber Cancer Institute’s childhood acute lympho-
blastic leukemia consortium protocols from 1995 to
2001 found that dexrazoxane reduced or prevented
doxorubicin-induced cardiac injury in children with
high-risk acute lymphoblastic leukemia, as indicated by
lower serum cardiac troponin T concentrations and pre-
served LV systolic function and structure without redu-
cing oncologic efficacy [3]. This has been found in
multiple additional pediatric studies, including those
from the Children’s Oncology Group [40, 41].
A single study is responsible for the unfounded fear
that dexrazoxane reduces the oncologic efficacy of
anthracyclines in adults, especially when used from the
beginning of anthracycline therapy [6]. The results of
this study have not been confirmed in other randomized
trials and retrospective studies in children and adults
with various cancers [40, 41].
As previously mentioned, secondary malignancies,
such as acute myeloid leukemia and myelodysplastic
syndrome, have been reported in studies of children re-
ceiving dexrazoxane [8]. However, this increased risk of
secondary malignancies was only observed in two ran-
domized controlled trials that administered etoposide
with doxorubicin and dexrazoxane; in other randomized
trials that did not include etoposide, the risk of acute
myeloid leukemia or other secondary malignancies was
not higher in the dexrazoxane arm [9]. Longer follow-up
of the same study patients with the initial concern about
secondary malignancies did not confirm this initial con-
cern [40]. Similarly, a single randomized trial that ad-
ministered cranial radiation to all patients (with either
T-cell acute lymphoblastic leukemia or non-Hodgkin
lymphoma) reported an increased rate of secondary
brain tumors in the dexrazoxane arm. No brain tumors
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developed in any of the 717 dexrazoxane-treated patients
enrolled in the other studies [9]. Overall, the concern for a
higher incidence of secondary malignancies with dexrazox-
ane use is unwarranted. In retrospective analyses of
long-term survivors of both childhood and adult cancers,
dexrazoxane was not associated with an increase in sec-
ondary malignancies when used with doxorubicin chemo-
therapy [9, 41, 42]. Long-term follow-up (median
follow-up, 12.6 years) of Children’s Oncology Group trials
has established that dexrazoxane neither reduces
long-term overall survival nor increases deaths from the
original cancer [40]. In fact, dexrazoxane use in pediatric
acute myeloid leukemia (AML) patients has shown better
3-year overall survival and event free survival [43].
Based on the efficacy of dexrazoxane as a cardioprotec-
tive agent in patients with a wide variety of cancers and
with evolving safety data demonstrating that it does not
impair chemotherapeutic efficacy and is not associated
with an increased risk of secondary malignancies, in 2015
the European marketing authorization holder for Cardiox-
ane (dexrazoxane; Clinigen Healthcare Ltd., Staffordshire,
UK) submitted an application to all relevant national regu-
latory authorities to widen the indication from “advanced
and/or metastatic adult breast cancer patients” to “cancer
patients” and remove the contraindication in children and
adolescents. The proposal to widen the indication was de-
clined. However, after a careful review of dexrazoxane’s
risk-benefit profile, the contraindication was lifted for chil-
dren and adolescents requiring high doses (≥300mg/m2)
of anthracyclines [44].
Baseline LVEF is a significant predictor of anthracycline-
induced cardiotoxicity [21]. Furthermore, while
anthracycline-induced cardiotoxicity is dose-dependent,
there is no threshold dose below which cardiotoxicity is
not observed [11]. Thus, patients with preexisting cardio-
myopathy are more susceptible to developing cardiotoxi-
city, even at lower anthracycline doses, and are often
excluded from receiving anthracyclines altogether [18, 45].
Dexrazoxane could be particularly useful in these patients,
but its use is limited by the current FDA and EMA label
[4]. In this case series, we demonstrate that the off-label
use of concomitant dexrazoxane in patients with preexist-
ing, asymptomatic LV dysfunction, allows successful
administration of anthracycline-based chemotherapy with-
out adverse cardiovascular outcomes.
Future perspective
Immunotherapies, including checkpoint inhibitors and
adoptive cellular therapy, as well as targeted therapy, are
now approved for several cancers and will likely change
the landscape of oncology in coming years [46–48]. How-
ever, many patients will still need anthracycline chemo-
therapy to be cured. Cardiotoxicity is a well-known side
effect of anthracyclines. Patients with preexisting cardio-
myopathy are at the highest risk for anthracycline-related
cardiotoxicity and are often denied lifesaving or sustaining
anthracycline-based chemotherapy, even when there is no
other alternative [18, 45]. Cardioprotection by dexrazox-
ane may offer a modality by which high-risk patients can
receive anthracyclines without significantly increased car-
diovascular morbidity and mortality [44].
Given that anthracycline-related cardiotoxicity can
occur at low doses in patients with preexisting cardiomy-
opathy, our case series supports the use of dexrazoxane in
this high-risk population from the beginning of anthracy-
cline therapy, rather than after a cumulative dose of 300
mg/m2 is reached. Furthermore, we would advocate
expanding its use to all cancers and not limiting it to pa-
tients with advanced breast cancer receiving doxorubicin.
In patients with normal LV systolic function, the decision
to administer dexrazoxane from the beginning of anthra-
cycline therapy versus after receiving a cumulative dose of
300mg/m2 may be debatable, but using dexrazoxane from
the initiation of anthracycline therapy should be consid-
ered, regardless of the type of cancer [49].
Although dexrazoxane is cardioprotective, its protection
is not complete and these patients should be monitored
closely for signs of clinical and even subclinical cardiotoxi-
city. Although there is no question that signs of clinically
significant cardiotoxicity may lead to interruption or re-
duction of anthracycline therapy, there is no consensus
among our authors, or many in this field, that withholding
or altering anthracycline therapy based solely on changes
in subclinical cardiovascular status (changes in LVEF or
serum cardiac biomarkers) will lead to a higher quality of
life for these patients.
Strengths and limitations of the study
This is a pragmatic study under real-world conditions. Al-
though bias is possible in any case series, by including
consecutive patients who met inclusion and exclusion cri-
teria and comparing the outcomes with a historical group
of anthracycline-treated patients who did not receive dex-
razoxane, we attempted to minimize bias. Our objectives
were clear, the outcomes were clinically relevant, and the
data were prospectively collected. Finally, there was no
loss to follow-up in either group. However, we recognize
the limitations of findings based on only a few patients
from a single center. Data collection in the patients
treated earlier without dexrazoxane was limited by its
retrospective nature.
Conclusion
Our results, albeit limited, support the use of concomi-
tant dexrazoxane for cardioprotection in patients with
preexisting cardiomyopathy from the beginning of
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anthracycline therapy, regardless of cancer type or stage.
Larger prospective trials are warranted to examine the
expanded use of dexrazoxane in high-risk patients, in-
cluding those with preexisting cardiomyopathy; cancers
other than those affecting the breast; and without a
minimum cumulative anthracycline dose.
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